Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Friday, May 25, 2018 · 448,659,682 Articles · 3+ Million Readers

Adventrx Pharmaceuticals To Raise $11.3 Million From Stock Sale

October 7, 2009 (FinancialWire) — Adventrx Pharmaceuticals, Inc. (AMEX: ANX) (Current Market Cap: $17.80 Mil.) said it has obtained commitments to purchase around $11.3 million shares of its series D convertible preferred stock.

The company plans to use the net proceeds from the offering to fund its operations during the FDA review period of an NDA for its ANX-530 product and to continue development of its ANX-514 product, and for general corporate purposes.

According to Adventrx, the preferred stock is convertible into shares of Adventrx common stock at the option of the investors at a conversion price of $0.18805 per share and will accrue a 4.25660% cumulative dividend until October 9, 2020.

Around $5.283 million of the gross proceeds will be placed in an escrow account, to be released to make dividend and other payments to the investors. The investors will also receive warrants to purchase an aggregate of 19.8 million shares of the company’s common stock.

San Diego-based Adventrx Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the safety of existing cancer treatments.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Powered by EIN Presswire